APONTIS PHARMA AG Annual General Meeting on May 12, 2022





When shareholders or their proxies register for the virtual Annual General Meeting, issue a proxy, exercise their shareholder rights, use the password-protected internet service, or connect to the virtual Annual General Meeting, we process personal data about these shareholders and/or their proxies (e.g. name, place of residence or registered office and address of the shareholder and, if applicable, his or her representatives, e-mail address, number of shares, class of shares, type of share ownership and number of the voting card, as well as access data for the password-protected internet service). This is done to enable shareholders or their proxies to connect to the virtual Annual General Meeting and to exercise their rights within the virtual Annual General Meeting.

The party responsible for processing the personal data of shareholders and their proxies is APONTIS PHARMA AG, Alfred-Nobel-Str. 10, 40789 Monheim, Germany, Tel.: +49 2173 8955 2204, email: peter.hagedorn@apontis-pharma.de.

The legal basis for the processing is Art. 6 (1) sentence 1 lit. b), c) and f) of the General Data Protection Regulation (GDPR). The personal data will be deleted as soon as they are no longer required for the aforementioned purposes and we are not obliged to continue storing them due to legal obligations to provide evidence and to retain records (e.g. according to the AktG, the German Commercial Code or the German Fiscal Code).

The Company's service providers, which we use for the purpose of organizing the Annual General Meeting, only receive personal data from the Company that is required for the performance of the commissioned service and process this data exclusively in accordance with the instructions of and on behalf of the Company.

In other respects, personal data will be made available to shareholders and shareholder representatives in connection with the Annual General Meeting in accordance with statutory provisions, namely via the list of attendees and in connection with the announcement of shareholder requests for additions to the agenda and of countermotions and election proposals by shareholders. The same applies in connection with the answering of questions which shareholders or shareholder representatives may have submitted in advance (Sec. 1 para. 2 sentence 1 no. 3 and sentence 2 COVID-19 Act).

Shareholders and shareholder representatives have a right of access, rectification, restriction, objection and deletion with regard to the processing of their personal data as well as a right to data transfer vis-à-vis the Company at any time, subject to the legal requirements set out in more detail in Art. 12 et seq. of the GDPR. You also have the right to lodge a complaint with a data protection supervisory authority pursuant to Art. 77 GDPR.

Our company data protection officer can be reached at the following contact details:

APONTIS PHARMA AG Data Protection Officer Alfred-Nobel-Str. 10 40789 Monheim

Tel.: +49 2173 8955 2204

Email: peter.hagedorn@apontis-pharma.de

Shareholders who authorize a proxy are requested to inform the proxy of the data protection notices.

Monheim am Rhein, March 2022

APONTIS PHARMA AG

The Executive Board